title: [Effect of simvastatin plus inulin in comparison with simvastatin plus ezetimibe on the treatment of mixed dyslipidemia].
abstract: BACKGROUND
  Mixed dyslipidemia accelerates atherosclerosis and leads to cardiovascular disease and death. Non-soluble fibers such as inulin have been shown to have an effect on dyslipidemia.
  
  
  OBJECTIVE
  To assess the effect of the combination of simvastatin plus inulin in comparison with simvastatin plus ezetimibe in mixed dyslipidemia.
  
  
  METHODS
  A randomized, double-blind, clinical trial with parallel control group was performed in 60 patients with mixed dyslipidemia, without drug treatment or failure to statins and lifestyle changes.
  
  
  METHODS
  simvastatin (20 mg), inulin from agave (7 g) and placebo of ezetimibe, or simvastatin (20 mg), ezetimibe (10 mg) and placebo of inulin from agave, daily at night, for 12 weeks.
  
  
  RESULTS
  Both groups decreased total cholesterol (235 ± 29 vs. 182 ± 42 mg/dl; p = 0.001 and 236 ± 31 vs. 160 ± 48 mg/dl; p < 0.001), low-density lipoprotein cholesterol (141 ± 32 vs. 99 ± 34 mg/dl; p < 0.001 and 149 ± 35 vs. 89 ± 43 mg/dl; p < 0.001) and triglycerides (284 ± 117 vs. 214 ± 137 mg/dl; p = 0.027 and 241 ± 81 vs. 180 ± 68 mg/dl; p < 0.001), respectively, for simvastatin plus inulin and simvastatin plus ezetimibe.
  
  
  CONCLUSIONS
  The combination of simvastatin plus inulin reduced total cholesterol, low-density lipoprotein cholesterol, and triglycerides the same as simvastatin plus ezetimibe.
authors: Instituto de Terapéutica Experimental y Clínica, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jal., México.|Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jal., México.
authors: Esperanza
authors: E
authors: Martínez-Abundis
authors: Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jal., México.
authors: Carmelita
authors: C
authors: Barrera-Durán
authors: Instituto de Terapéutica Experimental y Clínica, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jal., México.|Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jal., México.
authors: Manuel
authors: M
authors: González-Ortiz
authors: Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jal., México.
authors: Eduardo
authors: E
authors: Hernández-Salazar
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy*; D000069438:Ezetimibe / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007444:Inulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D007444:Inulin; D019821:Simvastatin; D000069438:Ezetimibe